Response to infliximab is related to disease duration in paediatric Crohn's disease.
Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A; Alimentary Pharmacology & Therapeutics, 2003, vol. 18, issue 4, p 425, ISSN 02692813. ISBN 02692813.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef